• Je něco špatně v tomto záznamu ?

Apolipoprotein E ?4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: A 15-year disease history model based on a 4-year longitudinal study

Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R.

. 2010 ; 56 (6) : 242-251.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc11006056

Grantová podpora
1A8713 MZ0 CEP - Centrální evidence projektů

Multiple sclerosis is a disease with considerable individual variation, and genetic background plays a key role in disease susceptibility and severity. The objective of the study was to evaluate the relationship between apolipoprotein E (APOE) genotype and the evolution of different clinical and MRI parameters. We investigated a group of 150 relapsingremitting patients that completed 4-year follow-up. The mean age was 30.2 years, disease duration 56.8 months, and baseline Expanded Disability Status Scale (EDSS) 1.8. The changes in brain parenchymal volume (BPV), gray matter (GMV), white matter (WMV) and peripheral gray volume (PGMV) were measured by SIENA/X. T2-lesion volume was assessed by semi-automated methods. The mixed-effect model analysis was used to investigate evolution of clinical and MRI parameters in relation to the APOE ?4 genotype considering two different time models: 4-year follow-up and 15-year period from disease onset. We identified 36 APOE ?4-positive patients. Decline of GMV (P = 0.017), and BPV (P = 0.029) were significantly faster in APOE ?4-positive than in APOE ?4-negative patients in the 15-year model. In the 4- year model, a trend for faster decrease of GMV was found in APOE ?4-positive patients (P = 0.067). No differences in other MRI parameters or EDSS were found between the APOE groups. The results of the study suggest that APOE ?4-positive patients experience faster rate of gray matter atrophy.

Bibliografie atd.

Lit.: 47

000      
00000naa 2200000 a 4500
001      
bmc11006056
003      
CZ-PrNML
005      
20140325144347.0
008      
110330s2010 xr e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Horáková, Dana $7 xx0076527
245    10
$a Apolipoprotein E ?4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: A 15-year disease history model based on a 4-year longitudinal study / $c Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vaněčková M, Krásenský J, Zivadinov R.
314    __
$a Charles University in Prague, First Faculty of Medicine, Department of Neurology and Center of Clinical Neuroscience, Prague
504    __
$a Lit.: 47
520    9_
$a Multiple sclerosis is a disease with considerable individual variation, and genetic background plays a key role in disease susceptibility and severity. The objective of the study was to evaluate the relationship between apolipoprotein E (APOE) genotype and the evolution of different clinical and MRI parameters. We investigated a group of 150 relapsingremitting patients that completed 4-year follow-up. The mean age was 30.2 years, disease duration 56.8 months, and baseline Expanded Disability Status Scale (EDSS) 1.8. The changes in brain parenchymal volume (BPV), gray matter (GMV), white matter (WMV) and peripheral gray volume (PGMV) were measured by SIENA/X. T2-lesion volume was assessed by semi-automated methods. The mixed-effect model analysis was used to investigate evolution of clinical and MRI parameters in relation to the APOE ?4 genotype considering two different time models: 4-year follow-up and 15-year period from disease onset. We identified 36 APOE ?4-positive patients. Decline of GMV (P = 0.017), and BPV (P = 0.029) were significantly faster in APOE ?4-positive than in APOE ?4-negative patients in the 15-year model. In the 4- year model, a trend for faster decrease of GMV was found in APOE ?4-positive patients (P = 0.067). No differences in other MRI parameters or EDSS were found between the APOE groups. The results of the study suggest that APOE ?4-positive patients experience faster rate of gray matter atrophy.
650    _2
$a financování organizované $7 D005381
650    _2
$a adjuvancia imunologická $x terapeutické užití $7 D000276
650    _2
$a dospělí $7 D000328
650    _2
$a antiflogistika $x terapeutické užití $7 D000893
650    _2
$a apolipoprotein E4 $x genetika $x imunologie $7 D053327
650    _2
$a atrofie $x patologie $7 D001284
650    _2
$a azathioprin $x terapeutické užití $7 D001379
650    _2
$a mozek $x patologie $7 D001921
650    _2
$a progrese nemoci $7 D018450
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a počítačové zpracování obrazu $7 D007091
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a interferon beta $x terapeutické užití $7 D016899
650    _2
$a longitudinální studie $7 D008137
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x genetika $x patologie $7 D020529
650    _2
$a nervová vlákna myelinizovaná $x patologie $7 D009413
650    _2
$a prednison $x terapeutické užití $7 D011241
700    1_
$a Kýr, Michal. $7 mub2014808498
700    1_
$a Kubala Havrdová, Eva, $d 1955- $7 nlk19990073204
700    1_
$a Doležal, Ondřej, $d 1979- $7 xx0075512
700    1_
$a Lelková, Petra $7 xx0142909
700    1_
$a Pospíšilová, Lenka $7 xx0142906
700    1_
$a Bergsland, N.
700    1_
$a Dwyer, M. G.
700    1_
$a Cox, J. L.
700    1_
$a Hussein, S.
700    1_
$a Seidl, Zdeněk, $d 1950- $7 mzk2004258727
700    1_
$a Vaněčková, Manuela, $d 1973- $7 mzk2007377403
700    1_
$a Krásenský, Jan $7 xx0096156
700    1_
$a Zivadinov, R.
773    0_
$w MED00011004 $t Folia biologica $g Roč. 56, č. 6 (2010), s. 242-251 $x 0015-5500
856    41
$u https://fb.cuni.cz/Data/files/folia_biologica/volume_56_2010_6/fb2010A0033.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y 2 $z 0
990    __
$a 20110330145758 $b ABA008
991    __
$a 20140325144421 $b ABA008
999    __
$a ok $b bmc $g 833564 $s 698145
BAS    __
$a 3
BMC    __
$a 2010 $b 56 $c 6 $d 242-251 $m Folia biologica (Praha) $x MED00011004
GRA    __
$a 1A8713 $p MZ0
LZP    __
$a 2011-05/mkme

Najít záznam